

В настоящее время наиболее актуальные подходы к сердечно-сосудистым исследованиям основаны на использовании кардиомиоцитов, дифференцированных из индуцированных плюрипотентных стволовых клеток (КМ-иПСК). Изучение активности ионных каналов на модели КМ-иПСК позволяют оценить биофизические свойства натриевых каналов в их нативном тканеспецифическом окружении с учетом генетического фона пациента.

КМ-иПСК активно используются для изучения ассоциированных с кардиомиопатиями изменений активности ионных каналов (Crasto, Di Pasquale, 2018; Steele-Stallard et al., 2018; Giacomelli et al., 2020; Shah et al., 2021). Однако в этих исследований авторы, как правило, ограничиваются изменениями плотности тока и не пытаются рассмотреть более детальные механизмы активности натриевых каналов. Так, на модели КМ-иПСК было показано уменьшение плотности тока в клетках пациентов с аритмогенной кардиомиопатией (Khudiakov et al., 2020), с дилатационной кардиомиопатией и прогрессирующим нарушением сердечной проводимости (Kamga et al., 2021) и в клетках пациентов с синдромом Бругада (El-Battawy et al., 2019; Zhu et al., 2021), а также замедление активации при миотонической дистрофии 1 типа (Poulin et al., 2021).

Актуальность данной работы во многом определяется тем, что в настоящее время большая часть данных, полученных на модели КМ-иПСК, фокусируется на описании изменений плотности натриевого тока и уровня экспрессии *SCN5A*, в то время как изучение других электрофизиологических характеристик натриевых каналов остается вне фокуса подавляющего числа исследований.

Мы продемонстрировали, что у пациентов с генетически обусловленными кардиомиопатиями, сопровождающимися желудочковыми аритмиями, ассоциированными с генетическими вариантами в генах *DSP* и *FLNC*, наблюдается усиление стационарной медленной инактивации. Это соотносится с данными литературы об изменениях медленной инактивации, обусловленных генетическими вариантами в гене *SCN5A*, ассоциированных с развитием желудочковых нарушений ритма. Например, при мутации T512I в гене *SCN5A* обнаружено изменение кинетики активации и инактивации и усиление медленной инактивации  $\text{Na}_v1.5$  (Yang et al., 2002), а генетический вариант G1712S сопровождался спектром биофизических изменений, в том числе нарушением медленной инактивации  $\text{Na}_v1.5$  (Sanner et al., 2021).

Таким образом, пока информации о роли процесса медленной инактивации  $\text{Na}_v1.5$  в развитии наследственных кардиомиопатий и аритмий недостаточно. Мы показали, что процесс медленной инактивации потенциал-зависимых натриевых каналов сердца может быть усилен в клетках пациентов с желудочковыми нарушениями ритма, вызванными генетическими вариантами в различных генах, регулирующих активность каналов  $\text{Na}_v1.5$  (*FLNC* и *DSP*).

## ФИНАНСИРОВАНИЕ

Работа выполнена при финансовой поддержке Российского фонда фундаментальных исследований (проект 20-34-90142).

## СОБЛЮДЕНИЕ ЭТИЧЕСКИХ СТАНДАРТОВ

Исследование одобрено этическим комитетом Национального медицинского исследовательского центра им. В.А. Алмазова и проводилось согласно надлежащей клинической практике и этическим стандартам Хельсинкской декларации. Все респонденты подписали информированное согласие на проведение необходимых методов обследования.

## КОНФЛИКТ ИНТЕРЕСОВ

Авторы заявляют об отсутствии потенциально-го конфликта интересов.

## СПИСОК ЛИТЕРАТУРЫ

- Зайцева А.К., Карпушев А.В., Жоров Б.С. и Костарева А.А. 2019. Биофизические механизмы натриевых каналопатий в миокарде: синдром удлиненного интервала QT. Российской физиол. ж. им. И. М. Сеченова. Т. 105. № 1. С. 3. (Zaytseva A.K., Karpushev A.V., Zhorov B.S., Kostareva A.A. 2019. Biophysical mechanisms of sodium channelopathies in myocardium: long QT syndrome and Brugada syndrome. Russian J. Physiol. V. 105. № 1. P. 3.)
- Adelman W.J., Jr., Palti Y. 1969. The effects of external potassium and long duration voltage conditioning on the amplitude of sodium currents in the giant axon of the squid, *Loligo pealei*. J. Gen. Physiol. V. 54. P. 589. <https://doi.org/10.1085/jgp.54.5.589>
- Akai J., Makita N., Sakurada H., Shirai N., Ueda K., Kitabatake A., Nakazawa K., Kimura A., Hiraoka M. 2000. A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. FEBS Lett. V. 479. P. 29.

- Amin A.S., Asghari-Roodsari A., Tan H.L.* 2010. Cardiac sodium channelopathies. *Pflugers Arch.* V. 460. P. 223. <https://doi.org/10.1007/s00424-009-0761-0>
- Balser J.R., Nuss H.B., Chiamvimonvat N., Pérez-García M.T., Marban E., Tomaselli G.F.* 1996. External pore residue mediates slow inactivation in mu 1 rat skeletal muscle sodium channels. *J. Physiol.* V. 494. P. 431.
- Bénitah J.P., Ranjan R., Yamagishi T., Janecki M., Tomaselli G.F., Marban E.* 1997. Molecular motions within the pore of voltage-dependent sodium channels. *Biophys. J.* V. 73. P. 603.
- Bénitah J.P., Tomaselli G.F. and Marban E.* 1996. Adjacent pore-lining residues within sodium channels identified by paired cysteine mutagenesis. *Proc. Natl. Acad. Sci. USA.* V. 93. P. 7392.
- Burridge P.W., Matsa E., Shukla P., Lin Z.C., Churko J.M., Ebert A.D., Lan F., Diecke S., Huber B., Mordwinkin N.M., Plews J.R., Abilez O.J., Cui B., Gold J.D., Wu J.C.* 2014. Chemically defined generation of human cardiomyocytes. *Nat. Methods.* V. 11. P. 855. <https://doi.org/10.1038/nmeth.2999>
- Capes D.L., Goldschen-Ohm M.P., Arcisio-Miranda M., Bezanilla F. and Chanda B.* 2013. Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels. *J. Gen. Physiol.* V. 142. P. 101.
- Crasto S., Di Pasquale E.* 2018. Induced Pluripotent Stem Cells to Study Mechanisms of Laminopathies: Focus on Epigenetics. *Front. Cell Dev. Biol.* V. 6. P. 172. <https://doi.org/10.3389/fcell.2018.00172>
- Dharmawan T., Nakajima T., Iizuka T., Tamura S., Matsui H., Kaneko Y., Kurabayashi M.* 2019. Enhanced closed-state inactivation of mutant cardiac sodium channels (SCN5A N1541D and R1632C) through different mechanisms. *J. Mol. Cell Cardiol.* V. 130. P. 88. <https://doi.org/10.1016/j.jmcc.2019.03.023>
- El-Battrawy I., Müller J., Zhao Z., Cyganek L., Zhong R., Zhang F., Kleinsorge M., Lan H., Li X., Xu Q., Huang M., Liao Z., Moscu-Gregor A., Albers S., Dinkel H., et al.* 2019. Studying Brugada Syndrome with an SCN1B variants in human-induced pluripotent stem cell-derived cardiomyocytes. *Front. Cell Dev. Biol.* V. 7. P. 261. <https://doi.org/10.3389/fcell.2019.00261>
- Emery A.E., Dreifuss F.E.* 1966. Unusual type of benign x-linked muscular dystrophy. *J. Neurol. Neurosurg. Psychiatry.* V. 29. P. 338. <https://doi.org/10.1136/jnnp.29.4.338>
- Giacomelli E., Meraviglia V., Camponotini G., Cochrane A., Cao X., van Helden R.W.J., Krotenberg Garcia A., Mircea M., Kostidis S., Davis R.P., van Meer B.J., Jost C.R., Koster A.J., Mei H., Miguez D.G., et al.* 2020. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. *Cell Stem Cell.* V. 26. P. 862. <https://doi.org/10.1016/j.stem.2020.05.004>
- Gusev K., Khudiakov A., Zaytseva A., Perepelina K., Makeenok S., Kaznacheyeva E. and Kostareva A.* 2020. Impact of the DSP-H1684R genetic variant on ion channels activity in ipsc-derived cardiomyocytes. *Cell Physiol. Biochem.* V. 54. P. 696. <https://doi.org/10.33594/000000249>
- Hodgkin A.L., Huxley A.F.* 1952a. Currents carried by sodium and potassium ions through the membrane of the giant axon of *Loligo*. *J. Physiol.* V. 116. P. 449. <https://doi.org/10.1113/jphysiol.1952.sp004717>
- Hodgkin A.L., and Huxley A.F.* 1952b. The dual effect of membrane potential on sodium conductance in the giant axon of *Loligo*. *J. Physiol.* V. 116. P. 497.
- Hodgkin A.L., Huxley A.F.* 1952c. A quantitative description of membrane current and its application to conduction and excitation in nerve. *J. Physiol.* V. 117. P. 500. <https://doi.org/10.1113/jphysiol.1952.sp004764>
- Hoogendoijk M.G., Potse M., Linnenbank A.C., Verkerk A.O., den Ruijter H.M., van Amersfoorth S.C., Klaver E.C., Beekman L., Bezzina C.R., Postema P.G., Tan H.L., Reimer A.G., van der Wal A.C., Ten Harkel A.D., Dalinghaus M., et al.* 2010. Mechanism of right precordial ST-segment elevation in structural heart disease: excitation failure by current-to-load mismatch. *Heart Rhythm.* V. 7. P. 238. <https://doi.org/10.1016/j.hrthm.2009.10.007>
- Itoh H., Shimizu M., Takata S., Mabuchi H. and Imoto K.* 2005. A novel missense mutation in the *SCN5A* gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. *J. Cardiovasc. Electrophysiol.* V. 16. P. 486.
- Itoh H., Tsuji K., Sakaguchi T., Nagaoka I., Oka Y., Nakazawa Y., Yao T., Jo H., Ashihara T., Ito M., Horie M., Imoto K.* 2007. A paradoxical effect of lidocaine for the N406S mutation of *SCN5A* associated with Brugada syndrome. *Int. J. Cardiol.* V. 121. P. 239. <https://doi.org/10.1016/j.ijcard.2007.02.007>
- Kamga M.V.K., Reppe M., Hescheler J., Nguemo F.* 2021. Modeling genetic cardiac channelopathies using induced pluripotent stem cells — *status quo* from an electrophysiological perspective. *Biochem. Pharmacol.* V. 192. P. 114746. <https://doi.org/10.1016/j.bcp.2021.114746>
- Karakikes I., Ameen M., Termglinchan V., Wu J.C.* 2015. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. *Circ. Res.* V. 117. P. 80. <https://doi.org/10.1161/circresaha.117.305365>
- Khudiakov A., Kostina D., Zlotina A., Yany N., Sergushichev A., Pervunina T., Tomilin A., Kostareva A., Malashicheva A.* 2017. Generation of iPSC line from patient with arrhythmogenic right ventricular cardiomyopathy carrying mutations in *PKP2* gene. *Stem Cell Res.* V. 24. P. 85. <https://doi.org/10.1016/j.scr.2017.08.014>
- Khudiakov A., Zaytseva A., Perepelina K., Smolina N., Pervunina T., Vasichkina E., Karpushev A., Tomilin A., Malashicheva A., Kostareva A.* 2020. Sodium current abnormalities and deregulation of Wnt/ $\beta$ -catenin signaling in iPSC-derived cardiomyocytes generated from patient with arrhythmogenic cardiomyopathy harboring compound genetic variants in plakophilin 2 gene. *Biochim. Biophys. Acta Mol. Basis Dis.* V. 1866. P. 165915. <https://doi.org/10.1016/j.bbadiis.2020.165915>
- Kodama M., Furutani K., Kimura R., Ando T., Sakamoto K., Nagamori S., Ashihara T., Kurachi Y., Sekino Y., Furukawa T., Kanda Y., Kurokawa J.* 2019. Systematic

- expression analysis of genes related to generation of action potentials in human iPS cell-derived cardiomyocytes. *J. Pharmacol. Sci.* V. 140. P. 325. <https://doi.org/10.1016/j.jphs.2019.06.006>
- Nijak A., Saenen J., Labro A.J., Schepers D., Loeys B.L., Alaerts M.* 2021. iPSC-cardiomyocyte models of brugada syndrome-achievements, challenges and future perspectives. *Int. J. Mol. Sci.* V. 22. P. 2825. <https://doi.org/10.3390/ijms22062825>
- Muravyev A., Vershinina T., Tesner P., Sjoberg G., Fomicheva Y., Čajbiková N.N., Kozyreva A., Zhuk S., Mamaeva E., Tarnovskaya S., Jornholt J., Sokolnikova P., Pervunina T., Vasichkina E., Sejersen T., et al.* 2022. Rare clinical phenotype of filaminopathy presenting as restrictive cardiomyopathy and myopathy in childhood. *Orphanet J. Rare Dis.* V. 17. P. 358. <https://doi.org/10.1186/s13023-022-02477-5>
- Palti Y., Adelman W.J., Jr.* 1969. Measurement of axonal membrane conductances and capacity by means of a varying potential control voltage clamp. *J. Membr. Biol.* V. 1. P. 431. <https://doi.org/10.1007/bf01869791>
- Payandeh J., Gamal El-Din T.M., Scheuer T., Zheng N. and Catterall W.A.* 2012. Crystal structure of a voltage-gated sodium channel in two potentially inactivated states. *Nature.* V. 486. P. 135.
- Perepelina K., Kostina A., Klauzen P., Khudiakov A., Rabino M., Crasto S., Zlotina A., Fomicheva Y., Sergushichev A., Oganesian M., Dmitriev A., Kostareva A., Di Pasquale E., Malashicheva A.* 2020. Generation of two iPSC lines (FAMRCi007-A and FAMRCi007-B) from patient with Emery-Dreifuss muscular dystrophy and heart rhythm abnormalities carrying genetic variant LMNA p.Arg249Gln. *Stem Cell Res.* V. 47. P. 101895. <https://doi.org/10.1016/j.scr.2020.101895>
- Perepelina K., Zaytseva A., Khudiakov A., Neganova I., Vasichkina E., Malashicheva A. and Kostareva A.* 2022. LMNA mutation leads to cardiac sodium channel dysfunction in the Emery-Dreifuss muscular dystrophy patient. *Front. Cardiovasc. Med.* V. 9. P. 932956. <https://doi.org/10.3389/fcvm.2022.932956>
- Poulin H., Mercier A., Djemai M., Pouliot V., Deschenes I., Boutjdir M., Puymirat J., Chahine M.* 2021. iPSC-derived cardiomyocytes from patients with myotonic dystrophy type 1 have abnormal ion channel functions and slower conduction velocities. *Sci Rep.* V. 11. P. 2500. <https://doi.org/10.1038/s41598-021-82007-8>
- Raffaele Di Barletta M., Ricci E., Galluzzi G., Tonali P., Mora M., Morandi L., Romorini A., Voit T., Orstavik K.H., Merlini L., Trevisan C., Biancalana V., Housmanowa-Petrusewicz I., Bione S., Ricotti R., et al.* 2000. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. *Am. J. Hum. Genet.* V. 66. P. 1407. <https://doi.org/10.1086/302869>
- Richmond J.E., Featherstone D.E., Hartmann H.A., Ruben P.C.* 1998. Slow inactivation in
- Rodina N., Khudiakov A., Perepelina K., Muravyev A., Boytsov A., Zlotina A., Sokolnikova P., Kostareva A.* 2021. Generation of iPSC line (FAMRCi009-A) from patient with familial progressive cardiac conduction disorder carrying genetic variant FLNC p.Val2264Met. *Stem Cell Res.* V. 59. P. 102640. <https://doi.org/10.1016/j.scr.2021.102640>
- Rohr C.A., Boeckman F.A., Baker C., Scheuer T., Catterall W.A., Klevit R.E.* 1999. Solution structure of the sodium channel inactivation gate. *Biochemistry.* V. 38. P. 855. <https://doi.org/10.1021/bi9823380>
- Rudy B.* 1975. Proceedings: slow recovery of the inactivation of sodium conductance in *Myxicola* giant axons. *J. Physiol.* V. 249. P. 22.
- Rudy B.* 1981. Inactivation in *Myxicola* giant axons responsible for slow and accumulative adaptation phenomena. *J. Physiol.* V. 312. P. 531.
- Sanner K., Mueller-Leisse J., Zormpas C., Duncker D., Leffler A. and Veltmann C.* 2021. A Novel SCN5A Variant causes temperature-sensitive loss of function in a family with symptomatic Brugada syndrome, cardiac conduction disease, and sick sinus syndrome. *Cardiol.* V. 146. P. 754. <https://doi.org/10.1159/000518210>
- Sato C., Sato M., Iwasaki A., Doi T. and Engel A.* 1998. The sodium channel has four domains surrounding a central pore. *J. Struct. Biol.* V. 121. P. 314.
- Sendfeld F., Selga E., Scornik F.S., Pérez G.J., Mills N.L., Brugada R.* 2019. Experimental models of Brugada syndrome. *Int. J. Mol. Sci.* V. 20. P. 2123. <https://doi.org/10.3390/ijms20092123>
- Shah P.P., Lv W., Rhoades J.H., Poleshko A., Abbey D., Caporizzo M.A., Linares-Saldana R., Heffler J.G., Sayed N., Thomas D., Wang Q., Stanton L.J., Bedi K., Morley M.P., Cappola T.P., et al.* 2021. Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes. *Cell Stem Cell.* V. 28. P. 938. <https://doi.org/10.1016/j.stem.2020.12.016>
- Shy D., Gillet L., Abriel H.* 2013. Cardiac sodium channel NaV1.5 distribution in myocytes via interacting proteins: the multiple pool model. *Biochim. Biophys. Acta.* V. 1833. P. 886. <https://doi.org/10.1016/j.bbamcr.2012.10.026>
- Steele-Stallard H.B., Pinton L., Sarcar S., Ozdemir T., Maffioletti S.M., Zammit P.S., Tedesco F.S.* 2018. Modeling Skeletal muscle laminopathies using human induced pluripotent stem cells carrying pathogenic LMNA mutations. *Front. Physiol.* V. 9. P. 1332. <https://doi.org/10.3389/fphys.2018.01332>
- Tohyama S., Hattori F., Sano M., Hishiki T., Nagahata Y., Matsuura T., Hashimoto H., Suzuki T., Yamashita H., Satoh Y., Egashira T., Seki T., Muraoka N., Yamakawa H., Ohgino Y., et al.* 2013. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. *Cell Stem Cell.* V. 12. P. 127. <https://doi.org/10.1016/j.stem.2012.09.013>
- Vilin Y.Y., Ruben P.C.* 2001. Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. *Cell Biochem. Biophys.* V. 35. P. 171. <https://doi.org/10.1385/cbb:35:2:171>
- Wang D.W., Viswanathan P.C., Balser J.R., George A.L., Jr. and Benson D.W.* 2002. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with

- atrioventricular conduction block. Circulation. V. 105. P. 341.
- Yan Z., Zhou Q., Wang L., Wu J., Zhao Y., Huang G., Peng W., Shen H., Lei J. and Yan N.* 2017. Structure of the  $\text{Na}(\text{v})1.4\text{-}\beta 1$  Complex from Electric Eel. Cell. V. 170. P. 470.
- Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C., Hohnloser S.H., Shimizu W., Schwartz P.J., Stanton M., Murray K.T., Norris K., George A.L., Jr., Roden D.M.* 2002. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. V. 105. P. 1943. <https://doi.org/10.1161/01.cir.0000014448.19052.4c>
- Zaytseva A.K., Karpushev A.V., Kiselev A.M., Mikhaylov E.N., Lebedev D.S., Zhorov B.S., Kostareva A.A.* 2019. Characterization of a novel SCN5A genetic variant A1294G associated with mixed clinical phenotype. Biochem. Biophys. Res. Commun. V. 516. P. 777.
- Zaytseva A.K., Kiselev A.M., Boitsov A.S., Fomicheva Y.V., Pavlov G.S., Zhorov B.S., Kostareva A.A.* 2022. Characterization of the novel heterozygous SCN5A genetic variant Y739D associated with Brugada syndrome. Biochem. Biophys. Rep. V. 30. P. 101249. <https://doi.org/10.1016/j.bbrep.2022.101249>
- Zhang X., Ren W., DeCaen P., Yan C., Tao X., Tang L., Wang J., Hasegawa K., Kumasaka T., He J., Wang J., Clapham D.E., Yan N.* 2012. Crystal structure of an orthologue of the  $\text{NaChBac}$  voltage-gated sodium channel. Nature. V. 486. P. 130.
- Zhu Y., Wang L., Cui C., Qin H., Chen H., Chen S., Lin Y., Cheng H., Jiang X., Chen M.* 2021. Pathogenesis and drug response of iPSC-derived cardiomyocytes from two Brugada syndrome patients with different  $\text{Na}(\text{v})1.5$ -subunit mutations. J. Biomed. Res. V. 35. P. 395. <https://doi.org/10.7555/jbr.35.20210045>

## ANALYSIS OF THE ROLE OF $\text{NaV}1.5$ SLOW INACTIVATION IN THE DEVELOPMENT OF INHERITED CARDIAC PATHOLOGY

**K. Zaytseva<sup>a, b, \*</sup>, K. I. Perepelina<sup>a, c</sup>, A. A. Kostareva<sup>a</sup>**

<sup>a</sup> World-Class Research Centre for personalized medicine, Almazov National Medical Research Centre,  
Saint-Petersburg, 197341, Russia

<sup>b</sup> Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences,  
Saint-Petersburg 194223, Russia

<sup>c</sup> Institute of Cytology, Russian Academy of Sciences, Saint-Petersburg, 194064, Russia

\* E-mail: zaytseva\_@almazovcentre.ru

Voltage-gated cardiac sodium channels  $\text{Na}_v1.5$  are responsible for the initiation and propagation of action potentials in cardiomyocytes. Dysfunction of  $\text{Na}_v1.5$  can be caused both by pathogenic variants in the *SCN5A* gene itself, which encodes  $\text{Na}_v1.5$ , and by genetic variants in the genes of other proteins, regulating channel activity and trafficking. The change of different phases of the action potential is determined by the strict temporal organization of activation and inactivation of various ion channels. Transitions between channel functional states (for example, to slow inactivated state) can be influenced by various factors and proteins interacting with the channel. Despite the fact that the process of slow inactivation of the channel has been known for several decades, its role in the mechanism of development of hereditary heart pathology remains unclear. In this work, using the patch clamp method in whole-cell leads, we studied changes in the process of slow  $\text{NaV}1.5$  inactivation under the influence of various mutations in structural genes (*DSP*-H1684R, *LMNA*-R249Q, *FLNC*-R1267Q, *FLNC*-V2264M) associated with a genetically determined myocardial pathology leading to dysfunction of cardiomyocytes. The study used a model of cardiomyocytes differentiated from induced pluripotent stem cells (CM-iPSCs). We have demonstrated an increase in slow inactivation in the model of CM-iPSCs obtained from patients with a phenotype of cardiomyopathy combined with ventricular arrhythmias. Thus, this work contributes to understanding the role of the slow inactivation process in the mechanism of the development of heart pathology.

**Keywords:** *DSP*, *FLNC*, gating, inherited arrhythmia, *LMNA*,  $\text{Na}_v1.5$ , slow inactivation